GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 51,420 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 51,420 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60. Following the completion of the transaction, the chief executive officer now owns 1,720 shares in the company, valued at approximately $162,505.60. This represents a 96.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Katherine Stueland also recently made the following trade(s):

• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The shares were sold at an average price of $78.18, for a total transaction of $1,407,709.08.
• On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total transaction of $805,951.75.
• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The shares were sold at an average price of $70.34, for a total value of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The shares were sold at an average price of $70.48, for a total value of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total transaction of $143,456.40.

GeneDx Stock Performance

Shares of NASDAQ WGS traded down $7.19 during trading on Friday, reaching $89.38. 725,309 shares of the stock traded hands, compared to its average volume of 909,701. The company has a 50-day moving average of $78.01 and a 200-day moving average of $53.19. GeneDx Holdings Corp. has a 52-week low of $2.85 and a 52-week high of $98.87. The stock has a market capitalization of $2.46 billion, a P/E ratio of -28.74 and a beta of 2.02. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.25. The business had revenue of $76.90 million for the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company’s revenue was up 44.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.82) earnings per share. Analysts forecast that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on WGS shares. Wells Fargo & Company boosted their price target on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. TD Cowen boosted their target price on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday. The Goldman Sachs Group increased their price target on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Finally, Craig Hallum boosted their price objective on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, GeneDx currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.67.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC bought a new position in shares of GeneDx in the second quarter valued at approximately $2,362,000. Chartwell Investment Partners LLC bought a new position in GeneDx in the 3rd quarter valued at $1,722,000. Charles Schwab Investment Management Inc. increased its holdings in shares of GeneDx by 304.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock worth $6,240,000 after purchasing an additional 110,666 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of GeneDx in the third quarter worth $325,000. Finally, Lisanti Capital Growth LLC purchased a new stake in shares of GeneDx in the third quarter worth $1,554,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.